The purpose of this study is determine if the use of Sotorasib is effective in patients with previously treated stage 4 or recuurent KRAS G12C mutated non-squamous non-small cell lung cancer (NSCLC). You must be diagnosed with NSCLC with a KRAS G12C mutation.
Contact phone
Tracy Bellefeuil | 517.364.2835
Contact email
cancerclinicaltrials@sparrow.org
Principal investigator
Dr. Gordan Srkalovic, MD, PhD
Trial Category
Cancer
Trial SubCategory
Metastatic Non-Small Cell Lung
Webform